MCLEAN, Va.--(BUSINESS WIRE)--Zephyr AI, Inc. (“Zephyr AI”), a healthcare technology company committed to developing fast and explainable artificial intelligence (AI) solutions to democratize precision medicine, today announced the appointment of Rachael Brake, PhD, as its new Chief Scientific Officer..

弗吉尼亚州麦克莱恩（商业新闻短讯）--Zephyr AI，Inc.（“Zephyr AI”）是一家致力于开发快速且可解释的人工智能（AI）解决方案以实现精准医学民主化的医疗技术公司，今天宣布任命Rachael Brake博士为其新任首席科学官。。

“Having spent decades working in big pharma and biotech spanning roles in research, development and commercial, Rachael comes to Zephyr with a unique breadth of experience,” said Jeff Sherman, Zephyr AI Co-Founder, Interim CEO, and Chief Technology Officer. “She is a renowned scientist with an extensive background in oncology and precision medicine and a keen strategist skilled at developing and operationalizing cross-functional teams.

西风人工智能联合创始人、临时首席执行官兼首席技术官杰夫·谢尔曼（Jeff Sherman）表示：“雷切尔（Rachael）在大型制药和生物技术公司（biotech）工作了数十年，在研究、开发和商业领域发挥了跨越性的作用，他来到西风拥有独特的丰富经验。”。“她是一位著名的科学家，拥有肿瘤学和精准医学的广泛背景，并且是一位敏锐的战略家，擅长开发和运作跨职能团队。

Rachael’s mission-driven desire to simplify the complexities of personalized medicine is perfectly aligned with Zephyr’s commitment to address patients’ unmet needs and optimize outcomes.”.

雷切尔以使命为导向，希望简化个性化医疗的复杂性，这与西风致力于解决患者未满足的需求并优化结果是完全一致的。”。

Brake, who will lead Zephyr AI’s scientific, strategic, and commercial efforts, is the former Chief Scientific Officer at Corbus Pharmaceuticals where she built and led a novel research and development team focused on precision medicine and immuno-oncology; delivered two clinical stage oncology programs; and reinvigorated Corbus’s investment thesis.

Brake将领导Zephyr AI的科学，战略和商业努力，是Corbus Pharmaceuticals的前首席科学官，她在那里建立并领导了一个专注于精准医学和免疫肿瘤学的新型研发团队；提供了两个临床阶段的肿瘤学计划；并为科尔布斯的投资理论注入了活力。

Prior to her work at Corbus, Brake spent 11 years at Takeda Oncology, most recently as Head of U.S. Medical Affairs Oncology. Her former roles at Takeda include Global Program Vice President and Associate Director in Translational Research. Brake began her career as a research scientist at the Western Australian Institute for Medical Research before moving to Amgen in the US where she worked as a principal scientist, overseeing target identification and establishing multidisciplinary, cross-functional research teams that delivered various drug candidates.

在Corbus工作之前，Brake在武田肿瘤学工作了11年，最近担任美国医学事务肿瘤学负责人。她曾在武田担任全球项目副总裁和转化研究副主任。Brake在西澳大利亚医学研究所（Western Australian Institute for Medical research）担任研究科学家，开始了她的职业生涯，然后前往美国安进（Amgen）担任首席科学家，负责目标识别，并建立了多学科、跨功能的研究团队，为各种候选药物提供服务。

A native of Australia, Brake graduated with honors from The Australian National University, earning a Bachelor of Science in molecular biology and biochemistry. She holds a PhD from the University of Western Australia..

Brake出生于澳大利亚，以优异成绩毕业于澳大利亚国立大学，获得分子生物学和生物化学理学学士学位。她拥有西澳大利亚大学的博士学位。。

“As a scientist, I have always been fascinated by the communication networks that are co-opted by cancer and how quickly they can adapt to outsmart current therapeutic strategies,” Brake said. “As a strategist, I am equally intrigued by the potential of AI to quickly evolve our approaches to treatment so we can begin to turn the table on this life-threatening disease.

Brake说：“作为一名科学家，我一直着迷于癌症所选择的通信网络，以及它们能够以多快的速度适应当前的治疗策略。”。“作为一名战略家，我同样对人工智能迅速发展我们的治疗方法的潜力感兴趣，这样我们就可以开始扭转这种威胁生命的疾病的局面。

AI holds great potential to not only inform our treatment strategies; I believe it will also mobilize our industry to unlock novel approaches to tackling cancer and cardiometabolic disease. I’m thrilled to be joining the incredibly talented Zephyr AI team at such a pivotal time in clinical research.”.

AI不仅有很大的潜力为我们的治疗策略提供信息；我相信，这也将动员我们的行业开启应对癌症和心脏代谢疾病的新方法。在临床研究的关键时刻，我很高兴能加入极具天赋的Zephyr AI团队。”。

About Zephyr AI: Zephyr AI is a high-growth healthcare technology company committed to radically reshaping precision medicine in oncology and cardiometabolic disease. Through partnerships and proprietary data, Zephyr AI is curating the world’s most comprehensive healthcare dataset and marrying it with cutting-edge artificial intelligence algorithms to generate novel, translatable insights to build tools and products that support patients and providers and fuel ongoing research.

关于Zephyr AI：Zephyr AI是一家高增长的医疗保健技术公司，致力于从根本上重塑肿瘤学和心脏代谢疾病的精准医学。通过合作伙伴关系和专有数据，Zephyr AI正在策划世界上最全面的医疗保健数据集，并将其与尖端的人工智能算法相结合，产生新颖的可翻译见解，以构建支持患者和提供者并推动正在进行的研究的工具和产品。

At Zephyr AI, our mission-focused team of world-class software engineers and biologists leverage big data and next-generation technology to derive transformational insights and build enduring partnerships that will revolutionize the treatment of cancer and cardiometabolic disease. Visit us at www.zephyrai.bio and follow us on LinkedIn..

在Zephyr AI，我们以任务为中心的世界级软件工程师和生物学家团队利用大数据和下一代技术获得变革性见解，并建立持久的合作伙伴关系，这将彻底改变癌症和心脏代谢疾病的治疗方法。请访问www.zephyrai.bio并在LinkedIn上关注我们。。